Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

187 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cunningham D, et al. N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025. N Engl J Med. 2004. PMID: 15269313 Clinical Trial.
High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; EORTC Gastrointestinal Group. Wils J, et al. Eur J Cancer. 2003 Feb;39(3):346-52. doi: 10.1016/s0959-8049(02)00662-7. Eur J Cancer. 2003. PMID: 12565987 Clinical Trial.
The aim of this study was to investigate whether N-(phosphonacetyl)-L-aspartic acid (PALA) can enhance the activity of low-dose methotrexate (LD-MTX) modulated infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer. 198 patients were randomised either to (i) …
The aim of this study was to investigate whether N-(phosphonacetyl)-L-aspartic acid (PALA) can enhance the activity of low-dose methotrexate …
Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.
Annemans L, Van Cutsem E, Humblet Y, Van Laethem JL, Bleiberg H. Annemans L, et al. Acta Clin Belg. 2007 Nov-Dec;62(6):419-25. doi: 10.1179/acb.2007.061. Acta Clin Belg. 2007. PMID: 18351186
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
Van Cutsem E, Dirix L, Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M, Roth A, Morant R, Joosens E, Gruia G, Sibaud D, Bleiberg H. Van Cutsem E, et al. Br J Cancer. 2005 Mar 28;92(6):1055-62. doi: 10.1038/sj.bjc.6602462. Br J Cancer. 2005. PMID: 15756271 Free PMC article. Clinical Trial.
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E. Köhne CH, et al. Ann Oncol. 2008 May;19(5):920-6. doi: 10.1093/annonc/mdm544. Epub 2007 Dec 6. Ann Oncol. 2008. PMID: 18065406 Clinical Trial.
PATIENTS AND METHODS: Patients were randomly assigned to receive FOLFIRI: irinotecan (180 mg/m(2) i.v. on days 1, 15 and 22); FA (200 mg/m(2) i.v. on days 1, 2, 15, 16, 29 and 30); 5-FU (400 mg/m(2) i.v. bolus, then 22-h, 600 mg/m(2) infusion) or CAPIRI: irinotecan (250 mg …
PATIENTS AND METHODS: Patients were randomly assigned to receive FOLFIRI: irinotecan (180 mg/m(2) i.v. on days 1, 15 and 22); FA (200 mg/m(2 …
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients.
Bensmaïne, de Gramont A, Brienza S, Marty M, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Bleuzen P, Simon J, Cvitkovic E. Bensmaïne, et al. Eur J Cancer. 2000 Dec;36(18):2335-43. doi: 10.1016/s0959-8049(00)00305-1. Eur J Cancer. 2000. PMID: 11094307 Clinical Trial.
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Rougier P, et al. Lancet. 1998 Oct 31;352(9138):1407-12. doi: 10.1016/S0140-6736(98)03085-2. Lancet. 1998. PMID: 9807986 Clinical Trial.
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
Blijham G, Wagener T, Wils J, de Greve J, Buset M, Bleiberg H, Lacave A, Dalmark M, Selleslag J, Collette L, Sahmoud T. Blijham G, et al. J Clin Oncol. 1996 Aug;14(8):2266-73. doi: 10.1200/JCO.1996.14.8.2266. J Clin Oncol. 1996. PMID: 8708716 Clinical Trial.
A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.
Bleiberg H, Vandebroek A, Deleu I, Vergauwe P, Rezaei Kalantari H, D'Haens G, Paesmans M, Peeters M, Efira A, Humblet Y. Bleiberg H, et al. Acta Gastroenterol Belg. 2012 Mar;75(1):14-21. Acta Gastroenterol Belg. 2012. PMID: 22567742 Free article. Clinical Trial.
Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer.
Gerard B, Bleiberg H, Van Daele D, Gil T, Hendlisz A, Di Leo A, Fernez B, Brienza S. Gerard B, et al. Anticancer Drugs. 1998 Apr;9(4):301-5. doi: 10.1097/00001813-199804000-00002. Anticancer Drugs. 1998. PMID: 9635919 Clinical Trial.
One treatment cycle consisted of repeated administrations of 5-FU combined to folinic acid for six times and to oxaliplatin for three times over 50 days. 5-FU was given at the dose of 2.6 g/m2 as a continuous infusion over 24 h on days 1, 8, 22, 29 and 43 preceded by i.v. …
One treatment cycle consisted of repeated administrations of 5-FU combined to folinic acid for six times and to oxaliplatin for three times …
187 results
Jump to page
Feedback